Naptumomab estafenatox
 Schematic image of naptumomab estafenatox. VH, VL: variable (antigen binding) domains of antibody fragment | |
5T4 | |
|---|---|
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C3255H5025N855O1050S18 |
| Molar mass | 73513.02 g·mol−1 |
  (what is this?) (verify) | |
Naptumomab estafenatox (ABR-217620) is a
Mechanism of action
Chemically, it is a
T lymphocytes.[4]
See also
- Nacolomab tafenatox, a drug with a similar chemical structure and mechanism
References
- PMID 19636016.
- ^ Clinical trial number NCT00420888 for "ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma" at ClinicalTrials.gov
- ^ "Naptumomabum estafenatoxum" (PDF). WHO Drug Information. 20 (4): 291. 2006. Archived from the original (PDF) on 2011-02-01.
- PMID 24445502.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |